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Descriptions of the clinical features of Angelman syndrome (AS) have mainly been
focused on children. Here, we describe the evolution of the clinical phenotypes of
AS in adulthood, using clinical data from 95 individuals (mean age 31.6 years,
median 29.0 years, range 18–83 years), with genetically confirmed AS. Data was
collected through physical examination and inspection of medical records, com-
bined with questionnaires and interviews. Adults with AS experience substantial
debilitating health problems. Constipation, reflux, visual problems, scoliosis, behav-
ioral and sleeping problems occurred frequently and require appropriate attention.
Epilepsy was reported in 57% of adults, negatively affecting the level of function-
ing. Non-convulsive status epilepticus was not observed in the adults, however
some individuals developed prolonged episodes of rhythmic shaking while awake. A
decline in mobility was noted in the majority of adults. A minority of adults with AS
showed microcephaly. Taken together, this first phenotypic study of adults with AS
to include in person interviews with care-givers and physical examination of
patients, including the eldest adult reported to date, provides important insight in
the development of the syndrome into adulthood. This knowledge is required to
improve care for adult individuals with AS and to evaluate future therapies for this
group.
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1 | INTRODUCTION
Angelman syndrome (AS) is a rare neurogenetic disorder with an esti-
mated prevalence of about 1:20.000 (Mertz et al., 2013). AS is caused
by loss or dysfunction of the maternal UBE3A gene, which is in the
brain exclusively expressed from the maternally inherited chromosome
15. There are four different genetic or epigenetic causes that can lead
to AS. An interstitial deletion of the 15q11-13 region of the maternally
inherited chromosome is the most common cause of AS in approxi-
mately 70% of the individuals with AS. Other genetic causes are unipa-
rental disomy (UPD), imprinting center (IC) defects and mutations in the
UBE3A gene itself (Buiting, Williams, & Horsthemke, 2016).
AS is clinically characterized by severe cognitive impairment, epi-
lepsy, poor sleep, motor problems ataxia, and speech impairment.
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Individuals with AS have a typical behavioral phenotype that includes
interest in social interaction, frequent laughing, and hyperactivity. In
addition they often have facial dysmorphisms, such as microcephaly,
brachycephaly, wide spaced teeth, pointed chin, and macrostomia.
Clinical criteria of AS have been described by Williams and colleagues
(Williams et al., 1995; Williams et al., 2006).
Since Harry Angelman described AS for the first time in 1965
(Angelman, 1965), many studies have reported on AS in childhood
(Bindels-de Heus et al., 2020; Mertz et al., 2014; Tan et al., 2011;
Thibert, Larson, Hsieh, & Raby, 2013). This resulted in a clear picture
of the health issues of children with AS. Far less is known is about
the course of the syndrome in adulthood. Only a limited number of
studies described the course of the AS in adults (Buckley, Dinno, &
Weber, 1998; Clayton-Smith, 1993; Giroud et al., 2015; Guerrini
et al., 1996; Jacobsen et al., 1998; L. A. E. M. Laan, Den Boer,
Hennekam, Renier, & Brouwer, 1996; Leitner & Smith, 1996;
Minassian et al., 1998; Moncla et al., 1999; Penner, Johnston,
Faircloth, Irish, & Williams, 1993; Sandanam et al., 1997; A. Smith
et al., 1996; Williams & Frias, 1982; Williams, Gray, Hendrickson,
Stone, & Cantu, 1989). These studies mostly reported on small num-
bers of patients, the largest study describes 28 patients (J. C.
Smith, 2001). One recent study described a cohort of 110 adults
(Larson, Shinnick, Shaaya, Thiele, & Thibert, 2015). This study was
based on telephone interviews with parents or guardians. The adults
were not seen and a study of medical records was not included. In
addition, the mean age of this cohort is only 24 years. Adults with
AS over 40 years are rarely described in the literature, even though
adults with AS are anticipated to have normal life expectancy, based
on sporadic case reports of adults with AS over 50 (Bjerre, Fagher,
Ryding, & Rosen, 1984; Buckley et al., 1998; Duker, Van Driel, & Van
De Bercken, 2002; Jacobsen et al., 1998; L. A. E. M. Laan
et al., 1996; Meijers-Heijboer et al., 1992; Ronan, Buiting, &
Dudding, 2008), however good data about life expectancy is still
missing.
The aim of this study is to describe the evolution of AS in adult-
hood. By gaining more knowledge of the clinical spectrum of AS in
adulthood, care can be optimized to improve quality of life for adults
with AS. At the same time, natural history data will serve as an essen-
tial reference to evaluate future therapies that will be used in the
adult population.
2 | METHODS
From 2015 to 2018 adults with genetically confirmed AS were included
in this study to investigate the natural course of AS in adulthood. Adult
individuals with AS were recruited for the study via the Dutch Angel-
man parents association (vASN; Vereniging Angelman Syndroom
Nederland) and the Dutch Society of Physicians for persons with intel-
lectual disabilities. Furthermore adults visiting the outpatient clinic of
the Dutch ENCORE expertise center for neurodevelopmental disorders
(which includes the national AS expertise center) were approached to
participate.
Since adults with AS have an expressive language deficit and
severe cognitive impairment, they were considered incapable of giving
informed consent. Therefore, legal representatives, usually court
appointed parents or family members, who were interested in partici-
pation of their ward in the study, were sent information regarding the
study to decide upon participation of their ward in the study. Written
informed consent of the legal guardian was thereafter obtained.
The study was approved by the Medical Ethical Review Board of
the Erasmus Medical Center, Rotterdam (MEC-2015-267). Written
informed consent was obtained for all participants.
Three questionnaires were filled in by parents and/or caregivers
of participants. First a questionnaire requesting information on preg-
nancy, first clinical signs and symptoms, mental and motor milestones,
behavioral problems, sleeping problems, epilepsy, hearing and vision,
digestion and medical history. Secondly, two standardized question-
naires were used: the Aberrant Behavior Checklist-community (ABC-
C) and Sleep Disturbance Scale for Children (SDSC) (Bruni et al., 1996;
Marshburn & Aman, 1992).
The ABC-C is a behavior scale developed by Aman et al. to mea-
sure treatment effectiveness for people with intellectual disabilities
(Aman, Singh, Stewart, & Field, 1985). It consists of 58 items, which
indicates five subscales: irritability, lethargy-social withdrawal, stereo-
typic behavior, hyperactivity and inappropriate speech. Parents or
caregivers can rate each item on a four-point scale ranging from
0 (not a problem) to 3 (severe problem). The ABC-C has shown high
internal consistency, good inter-rater reliability, and a consistent five-
factor structure in multiple studies (Brinkley et al., 2007; Brown,
Aman, & Havercamp, 2002). Since the subscale “inappropriate speech”
was irrelevant to the AS population given that the vast majority of
individuals are nonverbal, we omitted the inappropriate speech scale
in this study.
The Sleep Disturbance Scale for Children (SDSC) is a screening
test to identify children with disturbed sleep. The SDSC is a 27-item
inventory rated on a 5 point Likert-type scale. The instrument's pur-
pose is to categorize sleep disorders in children. As well as giving an
overall score the instrument uses five subdomains: disorders of initiat-
ing and maintaining sleep, sleep breathing disorders, disorders of
arousal, sleep–wake transition disorders, disorders of excessive som-
nolence, and sleep hyperhidrosis. According to the developers of the
test, the SDSC had good diagnostic accuracy (AUC = 0.9 1) (Bruni
et al., 1996).
During an interview with parents and/or caregivers the com-
pleted questionnaires were discussed and corroborated. All questions
were asked in the same manner, following the questionnaires outline
and data were interpreted by the researchers together (IdB, AGH,
MJV). Clinical data were complemented by studying the medical
records.
In addition, parents and/or caregivers were interviewed with the
Vineland Adaptive Behavior Scales (VABS) by one of the researchers
(IdB, RFdJ, AGH, MJV). The VABS is a widely used instrument to
obtain an measure of adaptive functioning on the domains communi-
cation, daily living skills, socialization and motor skills indicating an
estimated developmental age (Sparrow & Cicchetti, 1985). The
DEN BESTEN ET AL. 169
reliability of the VABS in children and adolescents with intellectual
disabilities is proved to be good and the construct validity is high
(de Bildt, Kraijer, Sytema, & Minderaa, 2005).
All adults were seen for physical examination, which took place
immediately after the interview.
During physical examination, the focus was on the general health
condition, growth, skin, throat, nose and ears, eyes, lymph nodes,
heart, lungs, abdomen, back, arms, legs and joints. Photos were taken
of each adult and they were recorded on video, in order to describe
the facial characteristics and gait, if participants were ambulatory. To
reduce the burden of participation in the study for the adults with AS
and their caregivers, they were visited in their home environment by
the researchers.
The study was mainly cross sectional. Physical examination, VABS
and SDSC were performed once. Through the general questionnaire,
interviews and the study of medical records, a retrospective overview
of the medical history and clinical course was assembled.
For all participants the results of genetic tests were checked. The
diagnosis of AS had been confirmed by the standard tests at the time
of diagnosis, including methylation sensitive digestion, methylation-
specific PCR (MS-PCR), methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA), microsatellite marker
analysis (MSA), fluorescent in situ hybridization (FISH), MLPA analysis
of copy number, Comparative Genomic Hybridization (CGH)- or Single
Nucleotide Polymorphism (SNP)-array or single UBE3A gene sequenc-
ing (Beygo et al., 2019).
Data were analyzed using SPSS version 25 for windows. Descrip-
tive statistics and frequencies were used for calculations. For
genotype–phenotype correlations, adults with pathogenic variants in
UBE3A and UPD were grouped into a “non-deletion” group, and com-
pared to adults with a deletion of the 15q-11q13 PW/AS region
(Beygo et al., 2019). Differences between the groups were calculated
with independent t-tests for normally distributed continuous data or
categorical data a χ2 test was performed. For non-normally distrib-
uted data Mann Whitney U test was used.




Hundred and one adults with genetically confirmed AS were initially
included in the study. Six individuals from one large family, with a
novel maternally-inherited UBE3A sequence variant, presented with a
phenotype that did not match the clinical criteria for AS. These indi-
viduals were excluded from this report and were described separately
(Geerts-Haages et al., 2020).
The remaining 95 adults (48 males, 47 females) were included in
this study (Table 1). For 11 of these adults childhood data were
included in the Dutch study on health issues and development in chil-
dren with AS (Bindels-de Heus et al., 2020). The age ranges from
18 to 83 years, with a mean age of 31.6 years (median 29.0 years,
range 18–83 years). Type of genetic cause and type of genetic test
was recorded. In 19% of the cases the confirmed diagnosis was based
on an aberrant methylation test and no additional tests were done to
specify the subtype, they were classified as “undefined” (Table 1).
Except for two twin brothers with a pathogenic variant in UBE3A,
none of the adults were related.
Ninety-three adults were seen at least once over a period of more
than 3 years, from May 2015 till February 2019. For the two
remaining adults, permission was given to study medical records and
send questionnaires only. Table 2 shows an overview of the number
of available information sources. For some adults, parents and/or
caregivers were visited and adults were seen, but no permission was
given for physical examination.
TABLE 1 Patient characteristics
Full cohort (n = 95) %
Mean age 31.6 (SD: 12.6; range: 18–83)
Median age 29.0 (SD: 12.6; range: 18–83)
18–29 years 48 50.5
30–39 years 25 26.3
40–49 years 15 15.8
50–59 years 3 3.2
















UBE3A pathogenic variant 15 15.8
UPD 6 6.3
Undefinedb 18 18.9
Abbreviation: UPD uniparental disomy.
aThe ethnicity of parents was considered to describe ethnicity of the
adults, with parents together counting for 1. So if, for example, father
came from Spain and mother from the Netherlands, we noted 0.5 for both
groups.
bAll patients have genetically confirmed AS, but in some cases there were
no additional tests results available (only DNA methylation test).
Therefore, no distinction can be made between a deletion and UPD in
these cases.
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3.2 | Pregnancy and birth
Data on pregnancy was available for 91 cases. 77% of the pregnancies
were uneventful. Four cases of pre-eclampsia or hypertension were
reported and six cases of vaginal bleeding during pregnancy. The
remaining cases mentioned hyperemesis gravidarum, pyelonephritis or
frequent cystitis, hypothyroidism, extreme tiredness or limited move-
ment of the fetus.
The duration of the pregnancy was known in 87 cases. There was
a term pregnancy in 91%. The remaining 9% was late pre-term and
one individual was born preterm at 32 weeks. The birth weight was
known in 80 cases. The mean birth weight of a term individual with
AS was 3,117 g (range 1950–6,000). This is slightly lower than the
mean birth weight of Dutch newborns, which is 3,431 g (reference
CBS 2011/2013).
Six twin pregnancies were identified in 94 pregnancies. In these
twin pregnancies, intra uterine fetal death occurred twice. Three twins
consisted of one baby with AS and one unaffected baby, and in one
twin pair both children were affected with AS as a result of and
UBE3A variant. The average maternal age during these twin pregnan-
cies was 32 years (range 26–39 years).
In the majority (82%) of adults, the first signs / problems started
in the first few months after birth. In 65% of these individuals, feeding
problems were reported, such as little or no sucking reflex, poor swal-
low and frequent vomiting. In other individuals, poor sleeping, exces-
sive crying, icterus, heavy sweating, hernia inguinalis, postnatal
hypothermia, arching, absence of primitive reflexes such as walking
reflex and palmar grasp reflex, anal fistula, and anusatresia were men-
tioned. Although the first symptoms of AS started early, the median
age of diagnosis in this cohort is 6.8 years (mean 12.8 years, range
9 months–65.2 years). Notably, the age of diagnosis is lower in youn-
ger individuals, probably reflecting improved availability of genetic
testing. The median age of diagnosis in the age group of 18–29 years
is much lower with 2.5 years (mean 3.6 years, range 9 months–
14 years).
3.3 | Behavior
Behavioral data was available for 93 adults. In 86%, parents and/or
caregivers mentioned inappropriate behavior of the participant. Hair
pulling was mentioned most often, followed by hitting, screaming, skin
and nail picking, pinching, and biting. In more than 25%, this behavior
was considered problematic. However, the majority of parents and/or
caregivers indicated that this behavior was justifiable and perceived
this behavior rather as inappropriate communication rather than a
behavioral problem. Sixteen percent of the group with behavioral
problems used medication, most often Risperidone.
While hyperactivitity occurred in childhood in most individuals,
the majority of adults have become much calmer over the years,
according to their parents and/or caregivers. This decrease in hyper-
activity was already noticed in the youngest age group of
18–30 years. ABC-C subscale data are presented in Table 3.
TABLE 2 Sources of information
Full
cohort (n = 95) %
Physical examination 86 90.5
Natural course questionnaire 93 97.9
Aberrant behavior checklist (ABC-C) 89 93.7
Sleep disturbance scale for children
(SDSC)
88 92.6
Vineland adaptive behavior scales
(VABS)
92 96.8
Medical records 88 92.6
TABLE 3 SDSC and ABC-C subscales
SDSC DIMS SBD DA SWTD DOES SHY
(n = 69) [7–35]a [3–15]a [3–15]a [6–30]a [5–25]a [2–10]a
Mean (SD) 14,09 (5,28) 4,16 (1,81) 3,06 (0,34) 7,78 (2,73) 8,61 (3,73) 2,62 (1,44)
Median 13,00 3,00 3,00 6,00 7,00 2,00











Mean 7.25 4.52 2,62 8,92
(SD) (7.38) (5,48) (3,53) (8,1)
Median 6 3 1 8
Range 0–33 0–26 0–15 0–39
Abbreviations: ABC-C, Aberrant Behavior Checklist-Community; DA, arousal disorders; DIMS, difficulty
in initiating and maintaining sleep; DOES, disorders of excessive somnolence; SBD, sleep breathing
disorders; SDSC, Sleep Disturbance Scale for Children; SHY, sleep hydrosis; SWTD, sleep–wake
transition disorders.
aTheoretical range of subscale scores.
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3.4 | Epilepsy
Eighty-four adults had a history of seizures (Table 4). Of these, 45%
were seizure-free for at least 1 year, the majority with the use of anti-
epileptic drugs (AED). Medication failed to control epilepsy in 11%. This
group of adults suffered at least monthly from tonic–clonic (TC) seizures
or had daily smaller seizures, mostly atypical absences. We defined this
group as the “no control/active seizures”-group. The remaining 44% of
adults had partial control of their epilepsy, most of them had absences.
Episodes of non-convulsive status epilepticus had occurred in some
participants in childhood, with recurrent hospitalization reported in five
individuals. These episodes were not reported in adulthood. In a number
of adults prolonged episodes of rhythmic shaking without loss of con-
sciousness occurred. These episodes could be triggered by menstrua-
tion, tiredness of sudden changes of position.
The average age at onset of epilepsy was 3.3 years. Seventy-two
percent had their first insult before the age of 5 years and 22% were
between 5 and 10 years old during their first insult. Of the remaining
five individuals, a first insult occurred at 10, 12, 13, 20 or 22 years of
age. We found no correlation between the degree of response to
AEDs and the age at onset.
Out of 84 adults who had a history of seizures, 80% used AEDs
at the time of study. Most adults used one or two medicines in an
attempt to control the epilepsy. Valproate was the most commonly
used (49 times), followed by clobazam (16), levetiracetam (10), clonaz-
epam (9), ethosuximide (8), lamotrigine (8), carbamazepine (7),
fenobarbital (2), and nitrazepam (1).
The severity of epilepsy and the VABS data are presented in
Table 5. We found no clear correlation between the current degree of
seizure control and developmental age calculated by the VABS ques-
tionnaire. Participants without epilepsy did however have significant
higher VABS scores on the domains socialization and daily living skills
compared to participants with epilepsy. On the domain motor skills
participants without epilepsy achieved higher scores, although not sig-
nificant. The communication scores were not significantly different
between the groups.
3.5 | Sleep problems
Sleep data is presented in Table 6. Eighty-one adults had a history of
sleep problems, according to their parents and/or caregivers. Diffi-
culty falling asleep, frequent waking and waking up too early were
mentioned most. For 25% of individuals with a history of sleep prob-
lems, no change had occurred in the degree of sleep problems. In the
vast majority of the adults, an improvement or even disappearance of
the problems had been mentioned as they became older. Forty-one
percent of the adults with a history of sleep problems used sleep med-
ication, mainly melatonin with variable doses (range 0.1–5 mg). We
did not find relations between sleep problems, severity of epilepsy
and behavioral problems.
Data from the Sleep Disturbance Scale for Children (SDSC) was
available for 88 adults, but due to missing values a score could be cal-
culated for 69 adults only. Nineteen percent of the adults had a
TABLE 4 Epilepsy parameters
Cohort (n = 94) %
History of seizures 84 89.4
Current seizures n = 84
Seizure free/off AEDs 9 10.7
Seizure free/AED Tx 29 34.5
Partial control 37 44.0
No control/active seizures 9 10.7
Abbreviation: AED, antiepileptic drug.






seizures (n = 10)
Seizure
free (n = 37)
Partial
control (n = 36)
No
control (n = 9)
Communication 12 4–30 15 12 13 10
Daily living
skills
19 6–59 30 17 19 16
Socialization 12 2–52 17 11 12 12
Motor skills 18 1–37 25 17 18 14
TABLE 6 Sleep parameters
Cohort (n = 92) %
History of sleep problems 81 88.0
Course of sleep problems n = 81
Disappeared with age 29 35.8
Improved with age 30 37.0
Unchanged 20 24.7
Worsened with age 2 2.5
Sleep medication 33 40.7
Melatonine 28 34.6
Other sleep medicationa 6 7.4
aPromethazine, Alimemazine, Metroprolol, Midazolam, Clonazepam,
Clobazam.
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pathologic score, 1% a borderline score and 12% scored suspect for a
sleeping disorder. Sixty-eight percent had a normal score. In total 32%
had behavioral sleep disturbance concerning for a formal sleeping dis-
order according to the SDSC. Parents and/or caregivers reported
sleep problems in 57% of the adults at time of the study.
3.6 | Vision and hearing
Data about visual functioning were available for 92 adults. Of these
adults, 67% had a good vision, according to their parents and/or medi-
cal records. For 30% of adults, a reduced vision had been mentioned,
but only 18% wore glasses. Strabismus was seen in 32%, of which
2 adults had surgery in an attempt for correction. Two older individ-
uals of 63 and 83 years old suffered from cataracts, for one of them
the cataract had been treated with surgery. The decreased vision in
this adult was noted after she started to fall more frequently. In the
postoperative period, this was fully resolved.
Hearing was reported sufficient in 88 out of 90 adults, although
proper testing was rarely performed.
3.7 | Mobility
The majority of adults had been able to walk, with or without support
at some point in life, as shown in Table 7. The mean age at which
these adults started walking was 4.1 years. Only three adults had
never been able to walk. Thirty percent of the adults had been able to
walk long distances, which was defined as walks of several kilometers
and/or being able to walk during days out/trips. Another 39% did
walk independently, but only over short distances (10–100 m
or >100 m).
At the time of study, a mild decline in mobility was noticed in
27% of the adults, which was defined as more rigid or uncertain walk-
ing, more in need of support and/or more difficulty in climbing the
stairs. Twenty-two percent showed a serious decline, which was
defined as a shortening of the maximum walking distance, falling more
frequently or switching from walking into crawling. In 84% of the
adults 40 years and older, a decline in mobility was reported. Of the
adults who had been able to walk long distances, none showed a seri-
ous decline in mobility. Fifteen adults showed no change at all and for
nine individuals only a mild decline was reported. These nine adults
were scattered across all age categories. Decline in mobility is already
noted in some individuals from puberty, but is seen and is increasing
in every age category. In adults with visual problems, 61% showed a
decline in mobility, compared to 42% of the adults without visual
problems. However, this difference was not statistically significant.
3.8 | Nutritional status
Data was available for 91 adults. Almost half of the adults had trouble
to master themselves when it came to food. They could not stop eat-
ing, were insatiable or ate too greedy. For 12% of these adults, the
TABLE 7 Degree of mobility
Cohort n (%) 18–29 years 30–39 years 40–49 years 50–59 years >60 years
Mobility in the home n = 91 n = 45 n = 24 n = 15 n = 3 n = 4
Walks independently 59 (65) 30 15 11 2 1
Side arm assist or walking frame 12 (13) 3 5 3 — 1
Non-ambulatory 20 (22) 12 4 1 1 2
Mobility outside the home n = 89 n = 45 n = 23 n = 14 n = 3 n = 4
Walking independently 47 (53) 26 13 7 1 —
Side arm assist or walking frame 8 (9) 1 3 3 — 1
Wheelchair 34 (38) 18 7 4 2 3
Maximum distance at some point in life n = 92 n = 47 n = 24 n = 15 n = 3 n = 3
Never been able to walk 3 (3) 3 — — — —
Walks with support 25 (27) 13 8 1 1 2
Walks 10–100 m 12 (13) 6 3 2 1 —
Walks >100 m 24 (26) 7 8 8 — 1
Long distances 28 (30) 18 5 4 1 —
Mobility compared to the past n = 86 n = 43 n = 24 n = 12 n = 3 n = 4
Unchanged 42 (48) 29 10 1 1 1
Mild decline 23 (27) 8 8 6 1 —
Serious decline 19 (22) 5 5 5 1 3
Improved 2 (2) 1 1 — — —
Abbreviation: BMI, body mass index.
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parents and/or caregivers mentioned that the adult is nowadays more
in control. Ten percent of the adults were described as poor eaters.
Concerning constipation, data was available for 92 adults. Almost
90% suffered from constipation. Of these 65% used polyethylene gly-
col with the aim to control the constipation.
Dysphagia or frequent choking was reported in 45% of partici-
pants at time of study. Adults with dysphagia or frequent chocking
had pneumonia in medical history twice as often compared to adults
with no known swallowing disorder, respectively 32% and 15%.
Approximately one third of the adults suffered from gastroesophageal
reflux.
3.9 | Physical examination
Anthropometric and orthopedic data are presented in Table 8. The
average length of the males was 173 cm and of the females this was
162 cm. Twenty-five percent of the women were at least two stan-
dard deviations below the mean length of the Dutch population. In
men, this was the case for 22% of individuals.
Weight data was available for 78 adults. The mean Body Mass
Index was 24. One in ten men was underweight (BMI <18,5). There
was no underweight in the female group. In total almost 60% had a
healthy weight. Thirty-seven percent was overweight (BMI ≥25), of
which one third was obese (BMI ≥30). The male–female ratio in the
group with overweight/obesity was not quite equal. Among the men,
24% was overweight and in the female group almost 50% was
overweight.
Fifty percent of the adults showed a foot abnormality and con-
tractures existed in 22% of the adults, knees and hips contractures
were most frequent.
The majority of the adults had scoliosis. Of these 64% suffered
from mild scoliosis, of which 9% had worn a brace during puberty. In
22% of individuals, severe scoliosis was observed, of which more than
80% never had any form of therapy. One adult developed a severe
scoliosis despite wearing a brace and another one had worn a brace
and had undergone surgery, but still developed a severe scoliosis.
Fourteen percent have undergone surgery to correct their scoliosis
successfully. Five of the 11 adults with severe scoliosis were able to
walk without aid, the remaining 54% (6/11) were wheelchair bound.
Of the adults with mild scoliosis or with brace or surgical corrected
scoliosis, approximately 60% were able to walk independently and
16% with side arm assist/walking frame. Twenty-five percent were
wheelchair bound. In the group without scoliosis, only 11% were
wheelchair-bound.
Facial features are presented in Table 9.
TABLE 8 Anthropometrics and orthopedics
Total cohort % Male Female
Length n = 79 n = 36 n = 43
Mean 167 cm (SD: 9.94) 173 cm (SD: 7.74) 162 cm (SD: 8.80)
Normal 60 75.9 28 32
Small in length (≤ −2 SD) 19 24.1 8 11
Weight n = 78 n = 37 n = 41
Mean 68 kg (SD: 13.91) 69 kg (SD: 13.19) 67 kg (SD: 14.64)
BMI 18.5–25 45 57.7 24 21
Underweight (BMI < 18,5) 4 5.1 4 —
Overweight (BMI ≥25) 20 25.6 7 13
Obese (BMI ≥30) 9 11.5 2 7
Scoliosis n = 94 n = 47 n = 47
None 44 46.8 24 20
Mild 29 30.9 12 17
Severe 11 11.7 7 4
Surgical intervention 7 7.4 3 4
Corset treatment 3 3.2 1 2
Postural abnormalities n = 77 n = 32 n = 44
Pes planus 29 37.7 16 13
Pes equinus 8 10.4 5 3
Pes cavus 1 1.3 — 1
Other foot abnormalities 7 9.1 — 6
Other contractures 18 23.4 12 5
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3.10 | Development and skills
Average estimated developmental ages, as measured with the VABS
are presented in Table 10. As the table shows, there is little difference
in mean developmental age when it comes to adults from 18 to
50 years old. The group aged 50 to 59 showed a remarkably higher
average development age, but this small group consisted of two adults
with a UBE3A variant and one adult with an undefined AS genotype.
Adults older than 60 years scored lowest.
Data on daily living skills was available for 92 adults. Half of the
adults were not toilet trained. Of the remaining adults, half were toilet
trained and indicated that they had to go to the toilet, the other half
were clockwise trained. Most adults (59%) could eat independently
with cutlery (fork and spoon), the other adults needed help with eat-
ing, while 47% could drink independently, with or without a no-spill
cup. Parents and/or caregivers of 74 adults did not indicate a decline
in these skills with aging. Five adults became incontinent, while they
were toilet trained in the past and two adults lost their ability to eat
and drink independently.
3.11 | Communication
Twenty out of 92 adults were able speak some single words and two
adults were able to speak short sentences. All remaining adults were
completely nonverbal. Gestures, (icon)images and speech generating
devices were used by 26%, 28%, and 4%, respectively.
3.12 | Genotype–phenotype relations
The phenotype in adults with interstitial deletions of the 15q11-13
region appeared somewhat more severe. Adults from the non-
deletion group achieved significantly higher scores on the Vineland
domains socialization, motor skills and daily living skills compared to
participants with a deletion of the 15q11-13 region. On the domains
communication, scores were not significantly different between the
groups.
Adults with a deletion were diagnosed at a slightly younger age
compared to adults in the non-deletion group: mean age 34 versus
42 months (p = .16), which was not significantly different. Significantly
more adults in the deletion group suffered from epilepsy. Scoliosis
was found in 63% of adults in the deletion group to 45% in the non-
deletion group, but this comparison was also not significant. No differ-
ences were found in the severity of epilepsy, height and SDSC scores
and the occurrence of constipation, reflux, microcephaly, and sleep
problems between the groups (Table 11).
3.13 | Age at death and cause of death
Two adults died during the time frame of our study. One woman died
of urosepsis at the age of 83 years. Another woman died of double-
sided and metastatic breast cancer at the age of 49 years.
4 | DISCUSSION
Here we describe the clinical characteristics of the largest and
oldest group of adults with AS reported to date. Clinical findings
described represent a combination of questionnaire data, inter-
views with care givers, review of medical records (including genetic
etiology) and physical examination. This is unique for this age group
and provides a complete overview of the clinical characteristics of
adults with AS.
As expected, our study cohort shows a similar distribution of
genetic subtypes as seen in previous large studies (Bindels-de Heus
et al., 2020; Mertz et al., 2013; Williams, Driscoll, & Dagli, 2010). There
were no peculiarities in this study group regarding the course of the
pregnancy and birth, which is in agreement with prior studies (Clayton-
Smith & Pembrey, 1992; Moncla et al., 1999; A. Smith et al., 1996).
Birth weight was approximately 200 g lower compared to the general
population, consistent with previous reports (Bindels-de Heus
et al., 2020; Clayton-Smith, 1992).
The high number of twin pregnancies was striking. In this study,
the number of twin births was 6 per 94 deliveries. This is four times
higher than the Dutch Twin Register reported and could not be
explained by maternal age (Glasner, van Beijsterveldt, Willemsen, &
Boomsma, 2013). As far as we know high numbers of twins are not pre-
viously described in Angelman or Prader-Willi patients in literature. We
cannot explain this high number other than coincidence, and a larger
group of individuals with AS is needed to make further statements.
First signs and symptoms were noticed in the first year after birth
in the majority of participants, and mainly consisted of feeding prob-
lems. Consistent with less access to advanced genetic testing in the
past, diagnosis was made at a median age of 6.8 years. For the youn-
ger individuals in this study median age of diagnosis of 2.5 years old,
which is comparable to the age of genetic testing in younger children
with AS in The Netherlands (Bindels-de Heus et al., 2020).
Most parents and/or caregivers (72%) mentioned a decrease of
the hyperactive behavior that existed in childhood, what corresponds
with previous studies (Clarke & Marston, 2000; Clayton-Smith &
Pembrey, 1992; L. A. E. M. Laan et al., 1996; J. C. Smith, 2001).
TABLE 9 Facial characteristics
Cohort size Characteristic present %
Flat occiput 91 65 71.4
Pointed chin 92 50 54.3
Prominent lower lip 92 49 53.2
Dribbling 92 46 50.0
Macrostomia 91 43 47.3
Microcephaly 88 27 30.7
Strabismus 91 30 33.0
Wide spaded teeth 82 18 22.0
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Hyperactivity scores on the ABC-C were considerably lower com-
pared the children with AS described by Sadhwani and colleagues
(Sadhwani et al., 2019). Parents often mentioned this diminished
hyperactivity the biggest change upon becoming adult. However,
behavior problems did not disappear simultaneously with the
decrease in hyperactivity. Parents and/or caregivers of 80 adults
reported inappropriate behavior of their ward and for 22 adults this
was perceived as problematic. Many parents thought this behavior
reflected a communication problem. This notion is supported by find-
ings from Didden et al., who suggested that problematic behavior
serves to some extent the goal of rejecting and protesting (Didden
et al., 2009). In several adults, parents stated that improving communi-
cation using aided communication reduced behavioral problems.
Aided communication was used by the minority of adult patients.
Although most appropriate communications methods used for adults
with AS should be studied further, communication should receive
proper attention in all adults with AS.
Epilepsy is one of the most significant health concerns for individ-
uals with AS. In our group 89% had a history of seizures, which is con-
sisted with prior studies, reporting incidences of 80 up to 96%
(Buckley et al., 1998; Buntinx et al., 1995; Clayton-Smith &
Pembrey, 1992; Galvan-Manso, Campistol, Conill, & Sanmarti, 2005;
L. A. E. M. Laan et al., 1996; L. A. Laan et al., 1997; A. Smith
et al., 1996; Thibert et al., 2009; Valente et al., 2006). The mean age
of onset of epilepsy of 3.3 years also corresponds with medical litera-
ture (Buntinx et al., 1995; Clayton-Smith & Pembrey, 1992; Galvan-
Manso et al., 2005; L. A. Laan et al., 1997; Pelc, Boyd, Cheron, &
Dan, 2008; Thibert et al., 2009). Five individuals developed epilepsy
between 10 and 22 years of age years, which indicates that children
without epilepsy still need to be closely monitored till adulthood. Epi-
lepsy negatively influenced the level of functioning.
Several studies have reported a decrease in seizures during late
childhood or puberty (Clayton-Smith & Pembrey, 1992b; Larson
et al., 2015; Pelc et al., 2008; Valente et al., 2006). However, Laan
et al. observed that 92% of the adults still experienced epileptic sei-
zures (L. A. Laan et al., 1997). In our study, in 54% of the adults with
epilepsy, seizures had been present in the past year. Two of them
experienced an exacerbation of epilepsy at the age of 19 and in the
mid-twenties. This is consistent with previous studies that suggest
that epilepsy becomes milder as with age, but an exacerbation of the
epilepsy around the age of 20 years is possible (Buckley et al., 1998;
J. C. Smith, 2001; Thibert et al., 2009).
Most frequent seizure types were atypical absences and tonic–
clonic seizures. Episodes of non-convulsive status epilepticus were
TABLE 10 Mean developmental age in months according to Vineland Adaptive Behavior Scales (VABS)
Full













Communication 12.5 4–30 12.6 12.0 12.9 20.3 7.0
Daily living
skills
19.0 6–59 18.8 17.6 21.4 35.0 9.3
Socialization 12.3 2–52 12.4 11.3 11.9 28.0 7.8




Age at diagnosis (median age in years) 7 11 .16
Epilepsy (%) 96.4 76.2 .01
Sleep problems (%) 92.6 85.0 .32
Length (<2SD) (%) 21.7 31.6 .40
Scoliosis (%) 62.5 45.0 .20
Microcephaly (%) 33.2 25.3 .57
Constipation (%) 87.0 95.0 .33
Reflux (%) 38.9 35.0 .76
VABS scores (mean age in months)
Communication 12 12 .79
Socialization 10 16 .00
Motor skills 15 24 .00
Daily living skills 16 25 .00
Abbreviation: VABS, Vineland adaptive behavior scales.
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not reported in adulthood. These episodes are difficult to recognize
and it is possible some episodes in adulthood were missed. Notably,
the pattern of epilepsy appears to change into adulthood. In a number
of adults, prolonged episodes of rhythmic shaking without loss of con-
sciousness had been observed. These episodes could be triggered by
menstruation or sudden changes in position, had a duration of several
minutes to hours and were very debilitating for some adults. Such epi-
sodes have been described in other cohorts as well (Guerrini
et al., 1996; Larson et al., 2015). Further study into the etiology, trig-
gers and treatment of these episodes should be performed to
optimize care.
Sleeping disturbances improved (or even disappeared) in the
majority of adults. However 32% of the adults still showed behavioral
sleep disturbance, which rated as a formal sleeping disorder according
to SDSC screening scale, while 57% of the caregivers reported sleep
problems at the time of the study. The identification of sleeping prob-
lems proved to be difficult and caregivers often claimed unaware of
the actual amount of sleep. An accurate and valid method to assess
sleep in individuals with AS remains to be studied.
Notably some parents mentioned diminished sleep problems soon
after their child started living in a care facility, which was objectified
by camera observations during the night. This could suggest that a
behavioral pattern can evolve in the home environment, which main-
tains the sleep problems. Conant et al. suggested that epilepsy and
use of AED may be related to higher degree of sleep disturbance in
these adults (Conant, Thibert, & Thiele, 2009). However, we did not
find any relation between sleep problems and epilepsy in our cohort
of adults, in accordance with Bindels-de Heus et al who could not
confirm a relationship in Dutch children (Bindels-de Heus et al., 2020).
Except for three adults, all adults over 40 years showed a decline
in mobility. Clayton-Smith et al. also observed a decline in mobility in
all adults over the years (Clayton-Smith & Laan, 2003). They claimed
mobility was affected by weight gain and development of scoliosis
(J. C. Smith, 2001). We could not confirm a relation between over-
weight or obesity and level of mobility. It was in fact remarkable that
the four adults who were underweight, were all wheelchair bound
outside the home. The degree of severe scoliosis in non-ambulators
was conspicuous. Out of 11 adults with severe scoliosis, six were
wheelchair bound outside the house. Scoliosis and the degree of
mobility could certainly have a causal relation, however if mobility is
affected by scoliosis or whether development of scoliosis is increased
by the limitations in mobility, is unknown. Therefore, we plead for
early and frequent monitoring of the spine and timely intervention. In
the current study, we did not gather longitudinal data on progression
of scoliosis in adults. Although scoliosis predominantly develops dur-
ing growth, it is interesting to investigate if progression of scoliosis
occurs in adults.
Caring for adults with AS, mobility should receive appropriate
attention. The ability to walk is likely influenced by weight, ataxia, mus-
cle tone, deviations and/or contractures of hips, knees, ankles and feet,
tremor and balance problems. More knowledge is needed to influence
these factors in order to preserve the ability to walk in adults.
In more than 30% of the adults in our cohort, visual problems
were reported. However, vision tests were often not performed in
these adults. The number of adults with visual impairment may be
underestimated, since the study of Michielleto et al. reported an inci-
dence of 97% of ametropia (Michieletto, Bonanni, & Pensiero, 2011).
Moreover, 32% of our adults had strabismus. It is remarkable that out
of four adults over sixty, two had developed cataracts. Buckley et al.
also mentioned cataract in three adults developed between the 55th
and 58th year (Buckley et al., 1998). This is important to monitor. In
addition, there are some cases of keratoconus and retinochoroidal
atrophy described in literature (Rufa et al., 2003; Sandanam
et al., 1997). In our cohort is keratoconus was described in the medical
files by an ophthalmologist in three adults. For most adults this was
unknown. It is likely to assume that visual problems are under-
estimated in adults with AS and important that clinicians are aware of
the possibility of ophthalmological and visual problems.
Most (89%) of the adults in our cohort suffered from chronic con-
stipation, which is comparable with a previous report (Larson
et al., 2015). This percentage of constipation is very high, even though
chronic constipation is already of frequent occurrence in adults with
intellectual disabilities. In a study in Dutch elderly people with intellec-
tual disabilities, chronic constipation occurred in 43.3% of adults
above 50 years of age (Evenhuis, 2014). Although constipation is only
mentioned as an associated (20–80%) feature in the Consensus for
Diagnostic Criteria, our results emphasize that it is very important to
be aware of constipation in adults with AS (Williams et al., 2006).
The mean Body Mass Index of 24 was rather high, but obesity
(BMI ≥30) was found in only 9% of our adults, which is lower than the
reported prevalence of obesity in the general Dutch elderly popula-
tion (10%). Obesity has been described particularly in adult women,
but this was not confirmed in this study (J. C. Smith, 2001). According
to data from CBS (Statistics Netherlands) the number of Dutch with
overweight (BMI ≥25) was nearly half of all adults (48%) in 2012,
which corresponds with the prevalence of overweight in our cohort of
46% (Centraal Bureau voor de Statistiek, 2013). The percentage of
adults who were underweight was higher in our study (9%), compared
to the general Dutch population (3%).
Although the adults we studied did not show a higher prevalence
of overweight and obesity, almost half of the care givers mentioned
difficulties of their child to master themselves with food. Frequently
they mentioned diets to preserve a healthy weight. We suspect the
care and focus on a healthy diet of these caregivers lead to the reduc-
tion of overweight and obesity in our cohort and recommend moni-
toring of weight and diet and appropriate support in adults with AS to
prevent obesity.
Microcephaly is often described as a characteristic of Angelman
syndrome. In the Consensus for Diagnostic Criteria microcephaly is a
frequent (>80%) clinical feature of Angelman syndrome (Williams
et al., 2006). Although median head circumference was below aver-
age, only 27 out of 88 adults (30.7%) showed microcephaly. This is
relevant in case of diagnosing elderly individuals with intellectual
disabilities.
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Since mobility tends to decline in adults with AS, we investigated
whether there is also decline of cognitive and other functions over
age. Overall, such decline was not evident. Parents of four adults
reported loss of abilities. Two adults (age 37 and 69 years) lost their
urine continence and two adults (age 23 and 42 years) could eat less
independent than before. As to the VABS results, by taking genotypic
variability into account, we did not observe an evident decline in cog-
nitive functioning. But a larger group, longitudinal design and exten-
sive cognitive testing is necessary to address this further.
Besides the fact that the prognosis of the syndrome is still
unknown, there is almost no data on life expectancy. Medical litera-
ture describes that people with Angelman syndrome have near normal
to normal life expectancy. This assumption is based on sporadic case
reports of people above 50 years of age with clinical features of
Angelman syndrome (Bjerre et al., 1984; Clayton-Smith & Laan, 2003;
Williams et al., 2010). The oldest individual who had been described
in the literature so far, was a 75 year old man (Bjerre et al., 1984). The
oldest individuals in our cohort were 63, 69, and 83 years old, and all
female.
An important factor that may affect the level of adaptive func-
tioning, severity of epilepsy, and possibly life expectancy is genotype.
Although there is a large diversity between adults with Angelman syn-
drome, which cannot be explained by genotype alone, we confirmed
the presence of more severe phenotypes in adults with 15q11-13
deletions (Moncla et al., 1999; A. Smith et al., 1996; Williams
et al., 2006). Adults with a deletion showed lower levels of adaptive
functioning on the domains socialization, motor skills and daily living
skills and more often suffered from epilepsy.
Interestingly no differences on the communication domain of the
VABS was found, while clinically adults with UPD and pathological
variants of UBES3A appeared to communicate slightly better. Since
almost all adults were however nonverbal, differences were subtle
and could apparently not be measured in our study. It would be inter-
esting to investigate means to further characterize the communication
in AS adults.
5 | STRENGTHS AND LIMITATIONS
Main strength of this study is the detailed description of clinical char-
acteristics of AS in adulthood, in the largest cohort of AS adults
reported to date. Data gathered are combination of questionnaire
data, interviews with care givers, review of medical records and physi-
cal examination of almost every individual, which is unique and pro-
vides a much more complete picture of health issues in adults with
AS. More knowledge on the natural course of AS is essential to evalu-
ate the effects of future therapies. Furthermore, we describe areas of
concern for physicians caring for adults with AS, hoping this knowl-
edge will improve their care.
A limitation of the study is mainly the cross-sectional design.
Future studies gathering information on the natural course should
preferably assemble longitudinal data.
Our study cohort shows a distribution of genetic subtypes as
seen in the general AS population (Williams et al., 2010). Unfortu-
nately, the precise genetic subtype was not available for 18 adults.
Besides no adults with an confirmed imprinting center defect were
included in our study.
In this study, the VABS was used to estimate the level of adaptive
functioning on the domains communication, daily living skills, sociali-
zation and motor skills. Although the VABS is widely used and con-
struct validity is presumably high, this tool is only used in children and
adolescents and not in the adult population, as for the SDSC that is
also studied in children only. Furthermore although considerable dif-
ferences in communication were observed by the researchers
between individuals with AS, this was not reflected in the VABS
scores on the domain communication. Further studies into methods
to provide more detailed information on functioning on the domain
communication of the adults with AS will have to be studied.
Data collected in this study were partly qualitative and open to
interpretation. This was especially the case in assessing for example
behavioral and sleeping problems. We tried to limit the bias of inter-
pretation through the use of the different questionnaires and
researchers discussed the outcomes together.
As expected, we had some missing medical data. Although this
could in part be substituted by interviews with care-takers after the
completion of the questionnaires, a large proportion of the data was
collected retrospectively, with a risk of recall bias. For nine adults, we
did not have consent for physical examination and in a small number
of patients, parts of the physical examination could not be completed
due to resistance. We were not able to include deceased patients in
the study and hence we could not gather reliable data on life
expectancy.
6 | CONCLUSION
This is the most comprehensive survey of health issues in adults with
AS, including physical examination and in person interviews with care-
givers, reported in literature to date. Adults with AS are relatively
healthy, but still have some serious debilitating health problems. Care
for adults with AS should focus on monitoring weight, visual function-
ing and management of epilepsy, behavioral and sleep problems, com-
munication, reflux, and constipation. Frequent monitoring of the spine
and timely intervention when scoliosis is developing is important as
well as the monitoring of mobility and factors associated with a
decline of mobility such as overweight and deviations and/or contrac-
tures of joints to prevent deterioration of walking.
To learn more about the course of AS in adulthood, a larger
cohort is required. To identify putative adult AS patients, it is impor-
tant to realize that only the minority of adults with AS have micro-
cephaly. Additional areas of future research include level of cognitive
functioning in relation to the age, life expectancy, ophthalmologic
pathology, further genotype–phenotype relations, and twin preg-
nancies. Furthermore, factors associated with the decline in
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mobility should be studied to prevent the deterioration of walking
seen in a large number of the adults with Angelman and features of
epilepsy in adulthood should be studied further in combination
with the most effective treatment of epilepsy, since epilepsy
proved to have a negative association with the level of cognitive
functioning and mobility.
Hopefully, the increase in knowledge on the natural course of AS
in adulthood will result in an earlier diagnosis and a subsequent
improvement in care.
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